Business Context and Reporting Period
Company: Salarius Pharmaceuticals, Inc. (Note: Input metadata referenced "Decoy Therapeutics," but the filing text identifies the registrant as Salarius Pharmaceuticals, Inc., trading as SLRX).
Reporting Period: Quarterly period ended March 31, 2020.
Business Overview: Salarius is a clinical-stage biotechnology company developing treatments for cancers with high unmet medical need, specifically focusing on epigenetic dysregulation. Its lead compound, Seclidemstat (SP-2577), is an inhibitor of the LSD1 enzyme. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Grant Revenue | $1,132,830 | $655,635 |
| Total Operating Expenses | $3,502,388 | $2,188,419 |
| Net Loss | $(2,083,816) | $(1,522,076) |
| Loss Per Share (Basic & Diluted) | $(0.22) | $(0.64) |
| Cash and Cash Equivalents (End of Period) | $9,646,940 | $5,771,247 |
| Working Capital | $8,821,668 | N/A |
| Accumulated Deficit | $(14,160,516) | $(6,662,513) |
Liquidity: As of March 31, 2020, the company held approximately $9.6 million in cash. Management believes this is sufficient to fund operations for at least 12 months from the filing date. The company received a $180,000 loan under the Paycheck Protection Program (PPP) in April 2020.
Material Changes vs. Prior Period
- Revenue Increase: Grant revenue increased by 73% ($477,195) compared to Q1 2019, driven by higher reimbursable expenses under the CPRIT grant.
- Expense Growth:
- R&D Expenses: Increased 135% to $1.64 million due to clinical trial production, consulting fees, and increased patient enrollment.
- G&A Expenses: Increased 25% to $1.86 million, primarily due to costs associated with the company's transformation into a public entity (insurance, listing fees, investor relations) and increased personnel costs.
- Financing Activity: Net cash provided by financing activities surged to $9.6 million (from $1.5 million in Q1 2019) following a public offering on February 11, 2020, which raised approximately $11.0 million in gross proceeds.
- Warrant Liability: A non-cash gain of $283,070 was recorded due to the change in fair value of warrant liabilities, driven by a decline in the company's stock price.
Outlook, Risks, and Management Commentary
- Going Concern: The company has incurred losses since inception and expects to continue incurring significant operating losses. While current cash is sufficient for 12 months, substantial additional capital will be required for clinical development.
- Clinical Trials: The company is conducting Phase 1/2 trials for Seclidemstat in Ewing sarcoma and Advanced Solid Tumors. Management reports minimal disruption to clinical programs from the COVID-19 pandemic as of the filing date, though future delays in enrollment or supply chain disruptions are possible.
- Nasdaq Compliance: On April 9, 2020, the company received notice from Nasdaq that its stock price fell below the $1.00 minimum bid requirement. The company has 180 days to regain compliance, though Nasdaq tolled this period through June 30, 2020, due to the pandemic. Failure to comply could result in delisting.
- Grant Status: The CPRIT grant (up to $18.7 million) has been extended through May 2020, with an application pending for an extension to November 30, 2020. Approximately $9.1 million remains available for drawdown.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.6 million cash balance against projected burn rates, considering potential delays in clinical trials due to COVID-19.
- Nasdaq Listing Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Grant Funding: Confirm the approval status of the CPRIT grant extension and the ability to meet matching fund requirements.
- Dilution Risk: Assess the impact of future equity financings required to fund operations, given the company's lack of product revenue.
- Clinical Progress: Track enrollment rates and data release timelines for the Ewing sarcoma and Advanced Solid Tumor trials.